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Commentary Problems in the reporting of acne clinical trials: a 
spot check from the 2009 Annual Evidence Update 
on Acne Vulgaris
John R Ingram1, Douglas JC Grindlay2 and Hywel C Williams*2
Abstract
In the course of producing the 2009 NHS Evidence - skin disorders Annual Evidence Update on Acne Vulgaris, 25 
randomised controlled trials were examined. From these, at least 12 potentially serious problems of trial reporting were 
identified. Several trials concluded no effect of a treatment yet they were insufficiently powered to exclude potentially 
useful benefits. There were examples of duplicate publication and "salami publication", as well as two trials being 
combined and reported as one. In some cases, an incorrect "within-groups" statistical comparison was made and one 
trial report omitted original efficacy data and included only P values. Both of the non-inferiority studies examined failed 
to pre-specify a non-inferiority margin. Trials reported as "double-blind" compared treatments that were dissimilar in 
appearance or had differing adverse effect profiles. In one case an intention-to-treat analysis was not performed and 
there was a failure to account for all of the randomized participants. Trial results were made to sound more impressive 
by selective outcome reporting, emphasizing the statistical significance of treatment effects that were clinically 
insignificant, and by the use of larger-sounding odds ratios rather than rate ratios for common events. Most of the 
reporting problems could have been avoided by use of the CONSORT guidelines and prospective trial registration on a 
public clinical trials database.
Introduction
Each year, NHS Evidence - skin disorders (a national spe-
cialist library funded by NICE, available at http://www.
library.nhs.uk/skin) publishes an Annual Evidence
Update on Acne Vulgaris, which is a search for new evi-
dence published or indexed in the last year [1]. NHS Evi-
dence - skin disorders also produces Annual Evidence
Updates on atopic eczema, psoriasis and skin cancer. The
purpose is to make our community of clinical users
(mainly dermatologists, general practitioners and nurses)
aware of newly published research studies, to discuss
their significance for clinical practice, and to warn of any
methodological issues in their interpretation.
The Annual Evidence Updates normally search for sys-
tematic reviews and guidelines, because of the potential
hazards in commenting on single randomized controlled
trials or RCTs [2]. However, as only one systematic review
on acne was found for our 2009 Annual Evidence Update,
which was published on 2nd March 2009, we also searched
for new RCTs published or indexed over the previous
year since the last Annual Evidence Update [1,3]. A full
description of the methodology and search strategies
used can be found on the Annual Evidence Update web
pages [1].
The RCTs that were found for the 2009 Annual Evi-
dence Update comprise a "spot check" of acne trials pub-
lished over a one year period. In the course of putting
together the Annual Evidence Update [1,3] the authors
w e r e  s t r u c k  b y  a  h i g h  f r e q u e n c y  o f  p r o b l e m s  i n  t h e
reporting and interpretation of these acne RCTs, which
are now highlighted in this article. Our perspective in this
commentary is not to condemn well-intentioned authors
but to highlight common problems that may not be
immediately obvious to a wider readership in the hope of
reducing bias, improving patient welfare and influencing
the future conduct and reporting of clinical trials on acne.
The problems highlighted in this commentary are not
restricted to acne trials and we hope that the examples
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given will help to provide further evidence for the need to
improve standards in the reporting of all clinical trials.
Discussion
From the 25 RCTs found for the 2009 Annual Evidence
Update, at least 12 major problems of trial reporting were
identified; these are listed in Table 1 in the order in which
the trials appeared in the Update [1].
Lack of power
The first problem identified was RCTs being insuffi-
ciently powered to provide evidence of no difference
between trial interventions. One study [4], designed to
assess the effect of exercise on acne, randomized a total of
30 teenage boys to avoid or perform exercise, and the lat-
ter group was further divided into those who showered 1
hour or 4 hours later. The small numbers in the three
g r o u p s  p r o d u c e d  v e r y  w i d e  c o n f i d e n c e  i n t e r v a l s  t h a t
illustrated the underpowered nature of the study. It was
reported as a pilot study but a power calculation had been
performed. A second study [5] which recruited 60 sub-
jects claimed equivalence between an oral acne therapy
and the same treatment in combination with topical
agents. However, an equivalence margin was not deter-
mined in advance and the equivalence claim was made on
the basis of non-significant tests for superiority, a prob-
lem frequently encountered in clinical trial reporting [6].
In essence, no evidence of an effect had been misinter-
preted as evidence of no effect.
Table 1: Common problems in the reporting of acne trials
Problem Description References
1. Insufficient power Underpowered trials can produce false negative 
results in superiority studies or incorrect claims of 
equivalence
Pediatric Dermatology [4]; Indian Journal of 
Dermatology, Venereology and Leprology [5]
2. Duplicate publication Publication of the same trial more than once can 
artificially enhance its impact and distort subsequent 
meta-analyses
American Journal of Clinical Nutrition [8]; 
Journal of the American Academy of 
Dermatology [9]; Contraception [11]; Cutis [12]
3. Incorrect statistical comparison A "within-groups" comparison from baseline may 
give positive results when the correct "between-
groups" comparison is negative
Archives of Dermatology [15]; Saudi Medical 
Journal [16]
4. "Salami publication" Splitting the results from a single trial to produce 
more than one publication can artificially increase its 
impact
Journal of Drugs in Dermatology [19,20]
5. Inferiority margin not pre-specified In non-inferiority studies, lack of a pre-specified 
inferiority margin means that the margin might have 
been chosen in retrospect to fit the data
Journal of Drugs in Dermatology [19,20]
6. Two independent trials combined and 
reported as one
Independent trials should be analysed and reported 
separately before combination in any subsequent 
meta-analysis
Cutis [22]; Journal of the American Academy of 
Dermatology [23]
7. Loss of masking due to trial therapies 
not considered in "double-blind" trials
Comparators with different physical characteristics 
or adverse effect profiles can cause loss of 
participant or investigator masking
European Journal of Dermatology[25]; 
International Journal of Cosmetic Science [26]
8. Stating P values without publishing 
outcome data
P values can be misleading without confidence 
intervals and original outcome data
Indian Journal of Dermatology [27]
9. Failure to account for all randomized 
participants
Absence of an intention-to-treat analysis raises the 
possibility of attrition bias due to loss of study 
participants before the primary endpoint
International Journal of Cosmetic Science [26]
10. Selective outcome reporting Multiple endpoints, rather than a single primary 
endpoint, allow "data fishing" in which only the 
positive outcomes are highlighted
Journal of Drugs in Dermatology [28]
11. Treatment effects statistically 
significant but clinically insignificant
Highly significant P values may mask a small 
improvement in disease severity that is insufficient 
to be of clinical benefit to patients
Journal of Drugs in Dermatology [29]
12. Odds ratios used to exaggerate 
treatment effect
Odds ratios can be misleadingly large when event 
rates are high - rate ratios give more understandable 
results
Contraception [11]Ingram et al. Trials 2010, 11:77
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Duplicate publication
There were two sets of duplicate publications, in which
the same trial was published more than once, identified in
the 2009 Annual Evidence Update. The first [7] was an
additional analysis in a subgroup of patients from a trial
on low glycaemic load for treating acne that had already
been reported twice. The original duplicate publications
[8,9] had been picked up by the 2008 Annual Evidence
Update [10]; the papers reported the same trial but failed
to cross-reference each other and the journal editors had
not been informed. In the second set of duplicate publica-
tions, primary efficacy outcomes were presented in one
paper [11] without indicating the presence of secondary
efficacy outcomes, with the latter then being presented in
a second paper four months later [12]. The secondary
efficacy variables were similar to the primary variables
and showed similar results. We believe that all relevant
trial results (especially efficacy results) should be pre-
sented in one paper. If there are good reasons to split the
results, the seminal index paper should make at least
some reference to the measurement of other outcomes
and whether there is a plan to publish them elsewhere.
Several issues arise from duplicate publication. There
could be distortion of any subsequent meta-analysis if the
study results are counted twice - such a problem has
already arisen with the duplicate publication on low gly-
caemic load [13]. In addition, journal copyright may be
infringed, and multiple articles take up additional journal
resources. It has also been demonstrated how duplicate
publications result in higher citations [14].
Testing the wrong thing
Another pitfall that we picked up was the issue in a paral-
lel group study of performing a "within-groups" compari-
son, rather than the correct "between-groups" analysis of
change from baseline. In its abstract, a study that com-
pared a computer presentation with a written informa-
tion handout stated benefit in favour of the computer
approach based on a within-groups comparison, despite a
non-significant between-groups comparison in the main
article text [15]. Another study of two topical treatments
for active acne only performed a within-groups compari-
son [16], so no account was made for the effect of natural
disease history, in particular regression to the mean.
Whether such erroneous highlighting of results is delib-
erate or accidental is unclear - we suggest that it can be a
ploy used by authors to try and "save face" in the light of
an essentially inconclusive study, especially as some jour-
nal editors and clinicians will not spot the lack of a cor-
rect between-groups statistic.
"Salami publication" and absent inferiority margins
"Salami publication" of a clinical trial involves splitting
the results from a single trial into several packages that
are then published separately and may artificially increase
the impact of the study [17]. This issue affected a three-
armed parallel groups study registered as a single trial on
the ClinicalTrials.gov database [18]. Two of the treatment
arms were separately compared with the third arm and
each comparison was published as a stand-alone trial
[19,20], albeit in the same journal supplement. It would
have been straightforward to report the results of all
three arms in a single publication. Neither publication
referenced the other. Another problem with the trial is
that it was reported as a non-inferiority study but details
of the 15% non-inferiority margin were not stated in the
ClinicalTrials.gov register entry, so it is uncertain
whether this margin was chosen prospectively or retro-
spectively. We also found an acne study that compared
the same antibiotic at a low dose compared with the stan-
dard dose for acne which was essentially a non-inferiority
trial, but no non-inferiority margin was specified [21].
Reporting two independent studies as one
Almost the reverse of duplicate publication is pooling the
results of more than one previously unpublished, inde-
pendent clinical trial in a combined analysis, rather than
reporting the results separately. Under such circum-
stances, the larger, combined analysis could produce a
significant result when individually the trials fail to reach
significance. Two pairs of RCTs combined in single analy-
ses were spotted in the Annual Evidence Update [22,23].
Results of the individual, independent studies were not
presented separately. In both cases these were industry-
funded studies of novel topical preparations conducted in
North America. It is presumed that two identical RCTs
were needed for FDA licensing approval. Whilst it is
sometimes appropriate to combine similar studies using a
formal meta-analytical approach, we suggest that it is
inappropriate to only present combined results in the pri-
mary publication of two pivotal RCTs [24].
Were they really "double-blind"?
In RCT s of topical therapy, particular care is needed to
ensure that the comparator preparations closely resemble
each other, to prevent loss of participant or investigator
masking. In placebo-controlled studies the ideal compar-
ator is the vehicle used for the active treatment, but this is
not necessarily possible in head-to-head studies of two
active treatments. One trial was reported to be "double-
blind" but it compared an acne cream with a gel [25],
which would differ in appearance and properties on the
skin. Another common reason for loss of blinding in
RCTs is a frequent adverse effect associated with one of
the treatments and not the other. In topical acne therapy,
skin irritation often differs between preparations and this
probably caused some loss of blinding in a topical retin-
oid trial reported to be double-blind [26].Ingram et al. Trials 2010, 11:77
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Absent data and missing patients
Good practice in trial reporting is concerned with pro-
viding as much original trial data as possible. Confidence
intervals are needed as well as just P values. Unfortu-
nately, one efficacy study failed to provide any trial data
and relied on stating P values along with a potentially
unrepresentative selection of clinical photographs [27].
Another issue of good practice with RCT reporting is to
account for all the patients randomized to prevent attri-
tion bias, with an intention-to-treat analysis and a pre-
specified method to deal with missing values. One trial
randomized 45 participants but included data for only 30
of them at the final 8 week endpoint; no data or explana-
tion were given about those participants who dropped
out of the study [26].
Data fishing, impressive P values, and "plumped up" odds 
ratios
There are several ways in which a trial report can make
the results appear more impressive than they really are.
One of these is to "data fish" amongst a large number of
outcomes, rather than focus on a single, pre-specified pri-
mary outcome. This was probably the case in an acne trial
that displayed only its positive outcomes in the abstract
[28]. Another issue is reliance on a statistically significant
effect that may be insignificant in clinical practice. An
impressive P value of 0.001 was used to justify the efficacy
of an acne therapy [29], but this equated to only a modest
11% reduction in the acne lesion count, which probably
would not be meaningful to a patient. Finally, use of more
impressive sounding odds ratios rather than rate ratios
was spotted [11] which will give an overestimate when
event rates are frequent [30].
Conclusion
One of the foundations of evidence-based practice is the
availability of high quality evidence on which to base clin-
ical decisions. Although some of the trials found in the
Annual Evidence Update were reported to a high stan-
dard, around a half contained potentially serious report-
ing problems and framing biases that could mislead the
clinical readership.
Many of the problems outlined in this article could have
been avoided by adherence to the CONSORT guidelines
[31] and prospective trial registration. CONSORT has
provided the gold standard for RCT reporting, and adop-
tion of the guidelines by many, but not all, journals has
ensured a standardized method of quality control. The
CONSORT list can also be used to aid trial design at the
planning stage. Prospective trial registration on a public
clinical trials database, or publication of the study proto-
col, is also very helpful for subsequent users of research
to ensure that primary endpoints are stated prospectively.
In essence, the study designers are asked to "nail their flag
to the mast" in advance in terms of their most important
endpoint. Again, adoption of this as a requirement for
publication by journals has helped to promote its use.
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